Rosenberg Noah L. 4
4 · Travere Therapeutics, Inc. · Filed Feb 5, 2021
Insider Transaction Report
Form 4
Rosenberg Noah L.
Chief Medical Officer
Transactions
- Award
Common Stock
2021-02-03+4,500→ 48,594 total
Footnotes (1)
- [F1](1) On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On February 3, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the DUPLEX study.